RT Journal Article SR Electronic T1 Immunohistochemical Biomarkers of Survival in Patients With Adenocarcinoma of the Uterine Cervix Receiving Chemoradiotherapy JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 3231 OP 3240 DO 10.21873/anticanres.13464 VO 39 IS 6 A1 YING-CHUN LIN A1 RUI-YUN CHEN A1 JI-AN LIANG A1 YAO-CHING HUNG A1 LIAN-SHUNG YEH A1 WEI-CHUN CHANG A1 WU-CHOU LIN A1 YIN-YI CHANG A1 SHANG-WEN CHEN YR 2019 UL http://ar.iiarjournals.org/content/39/6/3231.abstract AB Background/Aim: To determine the prognostic effects of immunohistochemical biomarkers for predicting chemoradiotherapy (CRT)-based treatment outcomes in patients with adenocarcinoma of the uterine cervix. Materials and Methods: This study included 42 patients receiving definitive CRT. According to the International Federation of Gynecology and Obstetrics staging system, 13, 21, and 8 patients were classified as having stage IB2, II, and III disease, respectively. Baseline immunohistochemical biomarkers, including those for hypoxia, cell proliferation, cell adhesion, immunogenicity, and evasion of apoptosis, were analyzed using tissue microarrays from biopsy specimens. Results: Myeloid cell leukemia-1 (MCL1) overexpression and the presence of pelvic lymph node metastasis were two prognostic factors for inferior cancer-specific survival. A higher H-score for c-MYC proto-oncogene, bHLH transcription factor (c-MYC) was associated with lower pelvic relapse-free survival. Conclusion: For patients with adenocarcinoma of the uterine cervix requiring definitive CRT, treatment outcomes can be stratified by the immunohistochemical biomarkers MCL1 and c-MYC for cancer death and local failure, respectively.